Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Roche’s proficiency at antibody engineering allows it to construct the next-generation molecules needed to translate scientific insights into therapeutic candidates.
You may also be interested in...
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
Roche's potential in the growing field of immuno-oncology has been a game of wait and see. But now that Tecentriq has launched, the company believes the components are in place to maintain its leadership position in oncology.
Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq